Table 3.
Cross tabulation of results from EBUS-TBNA, PET-reports, and target volume coverage analysis from patients with locally advanced NSCLC, stage IIIA-IIIC, treated with definitive or neoadjuvant radiochemotherapy. N = 675 LN-stations in 180 patients
| Nuclear medicine report positive | Nuclear medicine report negative | Irradiated LN-stations | Not-irradiated LN-stations | |
|---|---|---|---|---|
| EBUS-TBNA positive | 275 | 16 | 289 | 2 |
| EBUS-TBNA negative | 102 | 282 | 127 | 257 |
| Irradiated LN-station | 338 | 78 | ||
| Not-irradiated LN-station | 39 | 220 | ||
| Nuclear medicine report positive and EBUS-negative LN-stations | 64 | 38 | ||
| Nuclear medicine report negative and EBUS-positive LN-stations | 15 | 1 | ||
| Nuclear medicine report negative and EBUS-negative LN-stations | 63 | 219 |
Note: All numbers represent lymph node station (LN-station) counts.